BlackRock, Inc. Reports 4.7% Ownership Stake in Jade Biosciences Inc (JBIO)

On April 27, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a 4.7% ownership stake in Jade Biosciences Inc (JBIO). As of the event date on March 31, 2026, BlackRock beneficially owns 2,295,825 shares of common stock. This filing represents an increase from a previously reported 0.0% position, though the current stake falls below the 5% threshold, as indicated by the 'classOwnership5PercentOrLess' flag being marked 'Y'. Of the total shares held, BlackRock reports sole voting power over 2,257,003 shares and sole dispositive power over the full 2,295,825 shares. The filing was submitted as an amendment (No. 2) under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiary entities under BlackRock, Inc. are identified as the holders, with no single person's interest exceeding five percent of the total outstanding common shares.